In 2018, The Christie will start to treat patients in Manchester. UCLH in London is due to start treating patients in 2019. Both services will not treat all the patients who would be referred overseas straight away and overseas access to proton beam therapy will continue until both hospitals have fully developed their capacity.
The services we offer in paediatric, teenage and young adult, central nervous system, soft tissue sarcoma, and head and neck cancers are ideally suited to support patients receiving proton beam therapy.
The Greater Manchester and Oswestry Sarcoma Service (GMOSS) currently provide supra-network care to patients with bone and soft tissue sarcomas (STS) and covers a population of 7.5 million.
Neuro-oncology is provided by a large, cohesive and highly motivated multidisciplinary team (MDT) comprising clinical and academic specialists based at The Christie, SRFT and the University of Manchester. The neuro-surgical unit at SRFT is part of the Greater Manchester Neuro-sciences centre, and currently takes referrals from a population of 3.5 million.
Our service is one of the largest and best established in the UK. The Christie also has the largest non-surgical head and neck service in the UK.
Patients who are diagnosed with cancer often have other treatments (surgery and/or chemotherapy) as well as radiation therapy. It is important that patients have timely access to proton beam therapy as part of their integrated treatment pathway. We are engaging with future referrers and developing pathways for patients in preparation for the service. We are also working to ensure that there is accommodation available for visiting patients and families.
The Christie has a strong tradition of research and collecting outcomes after cancer treatment. We have plans in place to collect as much evidence as possible from the UK service and we will collect outcomes on every patient whether they are part of a trial or not.